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Abstract
Purpose—This study characterized 99mTc-Mebrofenin (MEB) and 99mTc-Sestamibi (MIBI)
hepatic transport and preferential efflux routes (canalicular vs. basolateral) in rat and human
sandwich-cultured hepatocytes (SCH).
Methods—99mTc-MEB and 99mTc-MIBI disposition was determined in suspended hepatocytes
and in SCH in the presence and absence of inhibitors and genetic knockdown of breast cancer
resistance protein (Bcrp).
Results—The general organic anion transporting polypeptide (Oatp/OATP) inhibitor rifamycin
SV reduced initial 99mTc-MEB uptake in rat and human suspended hepatocytes. Initial 99mTc-
MIBI uptake in suspended rat hepatocytes was not Na+-dependent or influenced by inhibitors.
Multidrug resistance-associated protein (Mrp2/MRP2) inhibitors decreased 99mTc-MEB
canalicular efflux in rat and human SCH. 99mTc-MEB efflux in human SCH was predominantly
canalicular (45.8±8.6%), and ~3-fold greater than in rat SCH. 99mTc-MIBI canalicular efflux was
similar in human and rat SCH; basolateral efflux was 37% greater in human than rat SCH. 99mTc-
MIBI cellular accumulation, biliary excretion index and in vitro biliary clearance in rat SCH were
unaffected by Bcrp knockdown.
Conclusion—99mTc-MEB hepatic uptake is predominantly Oatp-mediated with biliary excretion
by Mrp2. 99mTc-MIBI appears to passively diffuse into hepatocytes; biliary excretion is mediated
by P-gp. The SCH model is useful to investigate factors that may alter the route and/or extent of
hepatic basolateral and canalicular efflux of substrates.
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Introduction
Probe substrates are used to obtain an in vivo phenotypic measure of specific
biotransformation or transport pathways in preclinical or clinical species. Ideally, a transport
probe substrate would be specific for a single transport protein, relatively safe for healthy
human volunteer studies and metabolically stable. There are currently very few identified
transport probe substrates suitable for clinical use. Digoxin has been recommended as a P-
Corresponding author. Reprint Requests: UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, 311




Pharm Res. Author manuscript; available in PMC 2011 September 1.
Published in final edited form as:













glycoprotein (P-gp) probe in the FDA guidance
(http://www.fda.gov/Cder/drug/drugInteractions/default.htm), however, digoxin also is
transported by organic anion transporting polypeptides OATP1B3 and
OATP4C1. 99mTechnetium-mebrofenin (99mTc-MEB) and 99mTechnetium-sestamibi
(99mTc-MIBI) are candidate probe substrates for multidrug resistance associated protein 2
(MRP2) and P-gp, respectively.
99mTc-MEB is the 99mTc-labeled trimethylbromo analogue of acetanilidoiminodiacetic acid
commonly used in nuclear medicine for hepatobiliary scintigraphy and evaluation of
gallbladder dysfunction(1). This compound belongs to a class of agents that couples a
lidocaine-like structure, resulting in high liver extraction, with 99mtechnetium, which is ideal
for gamma scintigraphy(2). Several hepatic transport proteins involved in the hepatobiliary
disposition of 99mTc-MEB were characterized recently in expressed systems including
OATP1B1, OATP1B3, MRP2 and MRP3(3). 99mTc-MEB exhibited increased and
prolonged hepatic exposure measured by gamma scintigraphy in Mrp2-deficient TR− rats
compared to WT rats, suggesting that Mrp2 is involved in canalicular transport(4).
Furthermore, case reports have documented a failure to visualize the hepatobiliary tree after
administration of 99mTc-disofenin (DISIDA), the diisopropyl analogue of
acetanilidoiminodiacetic acid, when administered to patients with Dubin-Johnson syndrome
(MRP2-deficiency)(5). More than 98% of a 99mTc-MEB dose is taken up by the liver; the
hepatic excretion half-life of 99mTc-MEB is rapid (16min) and ~1.5% of the dose was
recovered in urine after 24 hours in humans(2).
99mTc-MIBI, a monovalent cation complex of 99mTc (99mTc-2-methoxyisobutylisonitrile), is
used clinically to assess myocardial perfusion; 99mTc-MIBI distributes into the heart in
proportion to blood flow and myocardial viability(6, 7). Decreased uptake of 99mTc-MIBI in
resistant cells also has been attributed to a lower membrane potential and reduced
mitochondrial density(8). Several groups have used 99mTc-MIBI as a functional P-gp probe
substrate in rodents and humans(9–12). Further investigations using cancer cells in culture
revealed that 99mTc-MIBI is a MRP1 substrate (13). In TR− rats, 99mTc-MIBI cumulative
recovery in bile, and liver activity profiles based on in vivo imaging, were similar compared
to WT rats, suggesting that Mrp2 is not involved, or other mechanisms compensate for
impaired hepatic excretion (14). In humans, 99mTc-MIBI undergoes renal elimination and
fecal clearance mediated by biliary excretion and possibly intestinal secretion [Cardiolite®
package insert;(3)].
99mTc-MIBI and analogs of 99mTc-MEB have been used as probe substrates to assess
interindividual variation in hepatic drug disposition(10, 15, 16). Coadministration of 99mTc-
MIBI with the P-gp inhibitors PSC833 and LY335979 resulted in prolonged hepatic
exposure(9, 11, 12). 99mTc-MIBI pharmacokinetics were altered in a cohort of cancer
patients with common single nucleotide polymorphisms (SNPs) in ABCB1 exons 12
(C1236T) and 26 (C3435T); the elimination rate constant was significantly decreased(10).
However, the mechanisms of 99mTc-MIBI hepatic transport have not been investigated fully,
including potential compensatory proteins involved in hepatobiliary disposition. The
purpose of the current study was to characterize the mechanisms of 99mTc-MEB and 99mTc-
MIBI uptake and excretion in rat and human hepatocytes. The processes involved in hepatic
uptake, basolateral efflux and canalicular excretion are too complicated to be completely
elucidated in vivo. Therefore, suspended hepatocytes were used to investigate hepatic uptake
mechanisms and sandwich-cultured hepatocytes (SCH) were used to elucidate the hepatic
efflux of 99mTc-MEB and 99mTc-MIBI. TR− rats serve as a useful tool to examine altered
hepatobiliary disposition in response to impaired Mrp2 function, and facilitate the
identification of compensatory basolateral and apical efflux mechanisms involved in 99mTc-
MEB hepatobiliary disposition.
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Dulbecco’s modified Eagle’s medium (DMEM), insulin, MEM non-essential amino acids
solution (100x), L-glutamine, insulin and penicillin G-streptomycin solution were purchased
from Invitrogen (Carlsbad, CA). Estradiol-17-β-D-glucuronide (E217G), para-
aminohippuric acid sodium salt (PAH), tetraethylammonium (TEA), rifamycin SV,
glycyrrhizic acid, clonidine, desipramine, ketoprofen, fetal bovine serum (FBS), Triton
X-100, dexamethasone, and Hanks’ balanced salt solution (HBSS) modified with (H-1387)
or without (H-4891) calcium chloride were obtained from Sigma-Aldrich (St. Louis, MO).
Collagenase (type 1) was obtained from Worthington Biochemical Corporation (Freehold,
NJ). BioCoat™ collagen I plates, Matrigel™ basement membrane matrix, and ITS+™
(insulin/transferrin/selenium) culture supplement were purchased from BD Biosciences
Discovery Labware (Bedford, MA). Bicinchoninic acid (BCA) protein assay reagents and
BSA for the protein assay standard were purchased from Pierce Chemical Co. (Rockford,
IL). 99mTc-MEB and 99mTc-MIBI were purchased as sterile doses on the day of the
experiment from Cardinal Health Nuclear Pharmacy (Research Triangle Park, NC). Ultima
Gold™ XR scintillation cocktail, 3H-PAH (3.28Ci/mmol) and 3H-E217G (45.8Ci/mmol)
were purchased from Perkin Elmer Life Sciences (Boston, MA). 14C-TEA (55mCi/mmol)
was purchased from American Radiolabeled Chemicals. MK-571 sodium salt was purchased
from Cayman Chemical Co (Ann Arbor, MI). N-(4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-
isoquinolinyl)ethyl]-phenyl)-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide
(GF120918) was a gift from GlaxoSmithKline (Research Triangle Park, NC). All other
chemicals and reagents were of analytical grade and available from commercial sources.
Animals
Male Wistar WT rats (201–312g) from Charles River Laboratories, Inc. and Mrp2-deficient
TR− rats bred at the UNC (228–306g; breeding stock obtained from Dr. Mary Vore,
University of Kentucky, Lexington, KY) were used for SCH studies. All animals acclimated
for one week before experiments. Rats were housed in an alternating 12-h light and dark
cycle with free access to water and food prior to surgery. All animal procedures complied
with the guidelines of the Institutional Animal Care and Use Committee (UNC, Chapel Hill,
NC).
Suspended Hepatocyte Isolation/Uptake Studies—Rat hepatocytes were isolated by
a two-step collagenase perfusion method as described previously(17). Viability, as
determined by trypan blue exclusion, was 90 to 95% (mean = 92%). CellzDirect, Life
Technologies (RTP, NC) kindly provided freshly isolated human hepatocytes in suspension.
Hepatocyte donors included a 60 yr old female Caucasian, and 63 and 69 yr old male
Caucasians, with no recent history of smoking or alcohol use. Hepatocyte viability, as
determined by trypan blue exclusion, was 90, 86 and 89%, respectively. Isolated hepatocytes
were suspended at 1 × 106cells/ml in cold modified Hank’s buffer with 10mM Tris/5mM
glucose (pH = 7.4) or Na+-free choline buffer (10mM Tris, 5mM glucose, 5.4mM KCl,
1.8mM CaCl2, 0.9mM MgSO4, 10mM HEPES and 137mM choline; pH = 7.4) and stored on
ice prior to conducting uptake studies(18). Hepatocyte suspensions were preincubated in
bottom inverted Erlenmeyer flasks (rat) or 16×100mm glass vials (human) at 37 C for 5min;
0.1% DMSO or chemical inhibitor was added 1min before, followed by 99mTc-MEB (5μCi/
mL), 99mTc-MIBI (5μCi/mL), 3H-E217G (1μM, 60nCi/mL), 14C-TEA (20μM, 60nCi/mL)
or 3H-PAH (0.2, 1 or 20μM, 60nCi/mL). The following concentrations of inhibitors were
selected based upon reported affinities for the given active transport processes: 20μM
rifamycin SV (Oatp1a1, Oatp1a4, OATP1B1, OATP1B3, and OATP2B1 inhibitor), 20μM
glycyrrhizic acid (Oatp1a1, 1a4 and 1b2 inhibitor), 200μM clonidine [organic cation
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transporter (Oct1) inhibitor], 10μM desipramine (Oct1 and 3 inhibitor), 5μM decynium 22
(OCT inhibitor), 10μM ketoprofen [organic anion transporter (Oat2) inhibitor]. Aliquots
(100μL) of the suspension were removed at timed intervals (up to 5min), placed in 0.4-ml
polyethylene tubes and centrifuged immediately through a top layer of silicone oil:mineral
oil (82:18, v/v; 100μL) and a bottom layer of 3M KOH (50μL). 99mTc-MEB and 99mTc-
MIBI in the cell pellet and supernatant were analyzed using a sodium iodide well counter
and corrected for decay (99mTc t1/2=6.01h). 3H-E217G, 14C-TEA or 3H-PAH were analyzed
by liquid scintillation counting. Adherent fluid volume was estimated with 14C-inulin as
described previously(19). Protein concentrations for individual hepatocyte suspensions were
determined with the BCA protein assay reagent kit (Pierce) as instructed by the
manufacturer. BSA, as supplied by the manufacturer, was used as a standard (0.2 – 1mg/
mL).
Sandwich-Cultured Hepatocyte Studies—CellzDirect, Life Technologies (RTP, NC)
provided human hepatocytes plated on six-well Biocoat™ plates and overlaid with
Matrigel™. Hepatocyte donors were a 56 and 64 yr old female Caucasian with no history of
smoking or alcohol use. Rat hepatocytes (>88% viability) were seeded [~1.5 × 106cells/well
(TR−) or 1.75 × 106cells/well (WT)] in 6-well BioCoat™ plates and overlaid with Matrigel™
basement membrane matrix as described previously(20). The culture medium was changed
every 24h until experiments were performed on day 4 of culture.
Efflux Studies—On day 4, efflux experiments were performed as previously
described(21) with modifications. Briefly, hepatocytes were rinsed with 2mL warm standard
buffer and incubated with 1.5mL of 99mTc-MEB or 99mTc-MIBI (5μCi/ml) in standard
HBSS for 20 min in a humidified incubator (95% O2, 5% CO2) at 37°C. Subsequently,
hepatocytes were rinsed vigorously twice with 2mL warm standard HBSS or Ca2+-free
HBSS (to maintain or disrupt tight junctions, respectively), and incubated with 1.5mL of the
same buffer supplemented with chemical inhibitors (100μM MK571 or 20μM GF120918) or
vehicle control (0.6% DMSO) for 20min at 37°C. The amount of 99mTc-MEB or 99mTc-
MIBI in the efflux buffer was sampled at 20min and medium was aspirated. Hepatocytes
were lysed as detailed above. Data were normalized to protein concentration in each well, as
described above. Samples were analyzed using a gamma counter and corrected for decay.
The amount of substrate was measured in the medium at 20min and in the lysed SCH at the
end of the efflux phase. The extent of basolateral and canalicular efflux was determined
based on the following equations and normalized to the total substrate mass preloaded in the
hepatocytes, which was determined as the sum of the substrate mass in the efflux medium
and in the hepatocyte lysate at the end of the efflux phase:
Accumulation Studies—The method to determine substrate accumulation in the bile
canalicular networks of SCH has been described previously(20, 21). Cells were incubated
for 10min at 37°C with 1.5mL of 99mTc-MIBI (0.5μCi/ml) with or without Bcrp
knockdown, and in the presence and absence of 2μM GF120918 in standard buffer.
Substrate uptake was corrected for nonspecific binding by subtracting uptake on blank six-
well Biocoat™ plates overlaid with Matrigel™. Hepatocytes were lysed as detailed above
and data were normalized to protein concentration in each well, as described above.
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The biliary excretion index (BEI, %) was calculated using B-CLEAR® technology [Qualyst,
Inc., Raleigh, NC; (21)]:
where substrate accumulation in the cells+bile compartments was determined in hepatocytes
preincubated for 10 min in standard buffer; cellular accumulation of substrate was
determined in hepatocytes preincubated for 10 min with Ca2+-free HBSS.
where AUC0-T represents the product of the incubation time (T) and the initial concentration
in the medium. In vitro Clbiliary values were scaled per kilogram body weight assuming the
following: 200 mg protein/g rat liver tissue and 40 g rat liver tissue/kg body weight(22).
RNA Interference (RNAi) Knockdown of Bcrp—The methods for packaging of
recombinant siRNA-expressing adenoviral vectors and infection of SCH have been
described previously(23). Briefly, after seeding hepatocytes on Biocoat™ plates and
changing seeding medium, cells were infected overnight with adenoviral vectors expressing
non-target siRNA (siNT), or siRNA targeting the rat Bcrp gene at positions 288–306
(siBcrp) at a multiplicity of infection of 20. Cells were overlaid 24h after seeding, and
cultured as described above. Bcrp knockdown was confirmed by Western blot analysis and
the in vitro Clbiliary of nitrofurantoin was determined using LC/MS/MS analysis, as detailed
previously(23).
Statistical Analysis—Statistically significant differences in the efflux data in rat SCH
were determined by a two-way analysis of variance for the factors of treatment and route of
efflux, which exhibited a significant interaction. Therefore, a one-way ANOVA was
performed on basolateral and canalicular efflux data individually for the factor of treatment
with Dunnett’s post hoc test. A one-way ANOVA was performed on the initial uptake data
in suspended hepatocytes with Dunnett’s multiple comparisons post hoc test. The criterion
for significance in all cases was p < 0.05.
Results
Uptake of 99mTc-MEB, 99mTc-MIBI, 3H-E217G, and 14C-TEA in Suspended Rat and Human
Hepatocytes
Preliminary experiments in suspended rat hepatocytes sampling over 60min indicated that
the linear range of uptake was 2.5, 1.5, 2.5, and 5min for 99mTc-MIBI, 99mTc-MEB, 3H-
E217G, and 14C-TEA, respectively. Therefore, subsequent experiments were conducted up
to the respective times to evaluate the initial uptake rate of each substrate. The Oct/OCT
inhibitors clonidine, desipramine and decynium 22, and the Oat/OAT inhibitor ketoprofen,
and the absence of sodium [substitution with choline-based buffer to rule out the
involvement of sodium taurocholate cotransporter (Ntcp/NTCP)] had marginal effects on the
initial uptake of 99mTc-MEB in WT rat and human hepatocytes compared to control (Fig.
1A and 2A). Initial 99mTc-MEB uptake was significantly reduced to 20.7 and 35.4% of
control in the presence of the Oatp/OATP inhibitor rifamycin SV in WT rat and human
hepatocytes, respectively (Fig. 1A and 2A). In WT rat hepatocytes, the Oatp inhibitor
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glycyrrhizic acid significantly reduced 99mTc-MEB initial uptake to 39.5% of control (Fig.
1A). Initial 99mTc-MIBI uptake in suspended WT rat hepatocytes was not influenced by
inhibitors or replacement of sodium with choline in the uptake buffer; all values were within
10% of control (Fig. 1B).
In order to confirm the specificity of the selected inhibitors, transport of probe substrates
was assessed in the presence of each inhibitor. As expected, initial hepatocyte uptake of the
Oatp probe substrate 3H-E217G was inhibited significantly to 15.5 and 23.8% of control in
the presence of rifamycin SV and glycyrrhizic acid, respectively, in suspended WT rat
hepatoyctes (Fig. 1C), and 51.5% of control in the presence of rifamycin SV in suspended
human hepatocytes (Fig. 2B). All other inhibitors had marginal effects on 3H-E217G uptake
in both WT rat and human suspended hepatocytes (Fig. 1C and 2B). Initial uptake of the Oct
probe substrate 14C-TEA was signficantly inhibited to 23.7% and 25.6% of control in the
presence of clonidine and desipramine, respectively, in suspended rat hepatocytes (Fig. 1D),
and significantly reduced to 54.2% of control in the presence of decynium 22 (Fig. 2C) in
suspended human hepatocytes. Interestingly, the Oatp1a1, Oatp1a4 and Oatp1b2 inhibitor
glycyrrhizic acid signficantly reduced 14C-TEA uptake by 62.1% compared to control in
suspended rat hepatocytes (Fig. 1D). The uptake of 20 μM 3H-PAH over 60 min was
marginally greater than background (data not shown), which was attributed primarily to
nonspecific binding to the hepatocytes. 3H-PAH uptake was not significantly influenced by
the presence of 50μM MK571 in the incubation medium (a known Mrp inhibitor added to
inhibit potential basolateral efflux).
Hepatobiliary Disposition of 99mTc-MEB in Rat and Human Sandwich-Cultured
Hepatocytes—99mTc-MEB canalicular efflux was slightly lower than basolateral efflux
over 20 min in SCH from control WT rats (15.3±5.7% vs. 25.0±6.7% of total preloaded
mass; Fig. 3A). In contrast, in human SCH, 99mTc-MEB canalicular efflux was greater than
basolateral efflux (45.8±8.6% vs. 16.7±0.6% of total preloaded mass). 99mTc-MEB
canalicular efflux was ~3-fold greater in human compared to rat SCH, while basolateral
efflux in human SCH was slightly lower than in rat SCH (Fig. 3A). 99mTc-MEB basolateral
efflux tended to be higher in TR− SCH (31.8±6.2% of total preloaded mass; Fig. 3A)
relative to WT values, while canalicular efflux of 99mTc-MEB in TR− SCH was negligible
(Fig. 3A). MK571 (100μM) decreased 99mTc-MEB canalicular efflux 85% in rat SCH and
30% in human SCH (Fig. 3A), but increased 99mTc-MEB basolateral efflux 136% in rat
SCH and 240% in human SCH (Fig. 3A). 99mTc-MEB hepatocellular content (cell only) at
the end of the 20-min efflux phase was slightly greater in rat SCH (58.7±7.3%) compared to
human SCH (37.6±8.0%) (Table 1), consistent with the species differences observed in the
total efflux of 99mTc-MEB in rat (40.3±5.4%) and human (62.4±8.0%) SCH.
Hepatobiliary Disposition of 99mTc-MIBI in Rat and Human Sandwich-Cultured
Hepatocytes—99mTc-MIBI basolateral efflux tended to be greater than canalicular efflux
over 20 min in SCH from WT rats (40.5±7.6 vs. 23.6±3.4% of total preloaded mass), TR−
rats (39.4±7.1 vs. 30.9±2.1% of total preloaded mass), and humans (64.0±4.2 vs. 25.4±6.0%
of total preloaded mass) (Fig. 3B). 99mTc-MIBI canalicular efflux was similar between
human and WT rat SCH, but basolateral efflux was 37% greater in human compared to WT
rat SCH (Fig. 3B). 99mTc-MIBI basolateral efflux was similar in SCH from TR− and WT
rats; likewise, canalicular efflux of 99mTc-MIBI was not altered in SCH from TR− compared
to WT rats (Fig. 3B). GF120918 (20μM) decreased 99mTc-MIBI canalicular efflux 1.5-fold
in rat SCH and 2.1-fold in human SCH. Interestingly, GF120918 also decreased 99mTc-
MIBI basolateral efflux in rat and human SCH (~2.3- and ~2.9-fold, respectively) (Fig. 3B).
Hepatocellular content of 99mTc-MIBI at the end of the 20-min efflux phase tended to be
greater in rat SCH compared to human SCH (Table 1), consistent with greater percent of
Swift et al. Page 6













total efflux of 99mTc-MIBI in human (89.4±1.8%) compared to rat (64.0±8.2%) SCH using
the 20-min efflux study design.
Using the 10-min accumulation study design, 99mTc-MIBI accumulation in cells+bile and
cells was determined in rat SCH; BEI and in vitro Clbiliary values were 18% and 4.07 mL/
min/kg, respectively. To examine whether Bcrp and/or P-gp were responsible for the biliary
excretion of 99mTc-MIBI in rat SCH, 10-min accumulation studies were conducted. 99mTc-
MIBI BEI (36.0 and 26.6%) and in vitro Clbiliary (8.08 and 9.73mL/min/kg) in day 4 WT rat
SCH were increased marginally by infection with adenoviral vectors expressing a non-target
control (siNT) or short hairpin RNA targeting rat Bcrp (siBcrp), respectively, compared to
noninfected SCH (Fig. 4A). 99mTc-MIBI BEI and in vitro Clbiliary were ablated in the
presence of 2μM GF120918 in siNT- and siBcrp-infected SCH, which resulted in a ~2-fold
increase in hepatocellular accumulation (cells only) of 99mTc-MIBI (Fig. 4A). As shown in
figure 4B, in day 4 rat SCH, protein levels of Bcrp (normalized by β-actin) in siBcrp-
infected cells were ~20% of those in control (siNT-infected) cells. No differences in
nitrofurantoin cellular accumulation, BEI, or in vitro Clbiliary in noninfected or control siNT-
infected rat SCH were noted (Fig. 4C). As expected, the cellular accumulation of
nitrofurantoin, a Bcrp substrate, was increased due to the ~6-fold decrease in BEI in siBcrp-
infected cells compared to control (siNT-infected) cells.
Discussion
The utility of 99mTc-MEB and 99mTc-MIBI as probe substrates for phenotyping the function
of specific hepatic transport proteins was confirmed using well-established in vitro methods.
Suspended hepatocytes and SCH were utilized from rats and humans to characterize hepatic
uptake and efflux mechanisms in combination with the use of “specific” chemical inhibitors,
as detailed in the methods, to examine the impact of hepatic transport modulation on the
disposition of 99mTc-MEB and 99mTc-MIBI. Suspended hepatocytes are used primarily to
investigate uptake mechanisms; the inability to differentiate between sinusoidal efflux and
canalicular excretion limits the utility of suspended hepatocytes for efflux studies (24–26).
Isolation of hepatocytes by collagenase digestion and conventional cell culture results in the
loss of many liver-specific functions, redistribution of canalicular membrane proteins, loss
of cell polarity and architecture including bile canaliculi, and the deterioration of hepatocyte
viability within several days (27–29). In contrast, hepatocytes cultured between two layers
of gelled collagen (sandwich-cultured configuration) retain more in vivo-like properties,
including formation of intact canalicular networks and polarized excretory function, and can
be used to investigate the hepatobiliary disposition of substrates (21, 30–35).
Model probe substrates [3H-E217G(36, 37); 14C-TEA(38–40); and 3H-PAH(41, 42)] were
evaluated in the presence and absence of the panel of inhibitors to confirm the specificity of
the selected inhibitors for Oatp/OATP (rifamycin SV and glycyrrhizic acid; Fig. 1C and 2B),
Oct/OCT (clonidine, desipramine, and decynium 22; Fig. 1D and 2C) and Oat2/OAT2
(ketoprofen; data not shown), respectively. Unexpectedly, the Oatp/OATP inhibitor
glyzyrrhizic acid significantly decreased 14C-TEA initial uptake to 37.9% of control,
suggesting that this inhibitor is not specific for Oatp isoforms because TEA is not a substrate
of the Oatps expressed in the rat liver(43). Surprisingly, incubation of freshly isolated rat
and human hepatocytes with 0.2, 1 or 20μM 3H-PAH over 60min in the absence and
presence of 50μM MK571, co-administered to inhibit potential basolateral efflux, resulted in
no measurable increase in activity above background. Carrier-mediated retrieval of human
OAT1 expressed in Xenopus oocytes and HEK293 cells from the cell membrane results in
decreased function(44). These findings suggest that Oat2/OAT2 may not be properly
localized to assess transport function in freshly isolated rat and human hepatocytes.
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Based on the specificity of the chosen inhibitors, 99mTc-MEB and 99mTc-MIBI hepatic
uptake was examined. 99mTc-MEB initial uptake was sodium-independent, and was only
affected by the Oatp/OATP inhibitors, rifamycin SV and glycyrrhizic acid (Fig. 1A and 2A).
These data support the hypothesis that 99mTc-MEB uptake is predominantly mediated by
Oatps/OATPs in rat and human hepatocytes, and is in agreement with data
demonstrating 99mTc-MEB is a substrate of OATP1B1 and OATP1B3 in HEK293
overexpressing cells(3).
99mTc-MIBI initial uptake in rat hepatocytes was not influenced by inhibitors or the absence
of sodium in the uptake buffer (Fig. 1B), suggesting that an active transport process is not
involved in 99mTc-MIBI hepatic uptake at these low concentrations. Concentrations
of 99mTc-MIBI were increased (5 – 200μCi/mL) to saturate a possible active transport
process, but partitioning of 99mTc-MIBI into hepatocytes was linear at designated time
points collected for 60min. These findings are consistent with previous reports that 99mTc-
MIBI uptake is a function of free diffusion based on electrical potentials across the plasma
and mitochondrial membranes, with localization in the mitochondria by electrostatic
forces(45). Therefore, 99mTc-MIBI uptake experiments were not conducted in suspended
human hepatocytes to conserve this limited resource.
Further studies were undertaken to examine the efflux processes involved in 99mTc-MEB
hepatic disposition. Remarkably, the canalicular efflux of 99mTc-MEB was ~3-fold greater
in human compared to WT rat SCH, whereas the basolateral efflux was comparable (Fig.
3A). Based on work by Li et al., total Mrp2/MRP2 protein was not significantly different in
day 4 rat and day 7 human SCH (~4fmol/μg protein) utilizing a quantitative LC-MS/MS
analysis(46). Thus, the species differences in canalilcular efflux of 99mTc-MEB observed in
the present study cannot be attributed to differences in the absolute amount of Mrp2/MRP2
protein primarily responsible for biliary excretion of 99mTc-MEB, but could be explained by
differences in affinity or maximum velocity, assuming that canalicular efflux is mediated
solely by Mrp2/MRP2. 99mTc-MEB total efflux also was greater in human compared to rat
SCH due to this increased canalicular efflux (Fig. 3A). 99mTc-MEB canalicular efflux was
completely ablated in TR− rat SCH. The Mrp2 inhibitor MK571 decreased 99mTc-MEB
canalicular efflux ~6.7-fold in rat SCH, but only 30% in human SCH (Fig. 3A). This
apparent discrepancy could be due to a potential species difference in the hepatic disposition
of MK571 leading to lower intracellular exposure of the inhibitor as a result of decreased
uptake and/or increased clearance in human hepatocytes. Although species differences in the
contribution of P-gp or BCRP to 99mTc-MEB canalicular efflux in human compared to rat
hepatocytes cannot be ruled out, the more likely explanation for these differences may be
attributed to limitations in the experimental design of the efflux experiments. During the
preloading phase, 99mTc-MEB accumulates in the canalicular networks and may not be
washed away completely before initiating the efflux phase; rapid canalicular excretion
of 99mTc-MEB may occur before MK571 had time to access the hepatocyte and reach the
site of MRP2 inhibition, especially in human SCH. Overall, MK571 inhibition and the
absence of 99mTc-MEB in the bile canalicular networks of TR− rat SCH support the
hypothesis that 99mTc-MEB is a specific Mrp2 probe substrate, consistent with other reports
documenting increased hepatic exposure of 99mTc-MEB in TR− rats(4), and decreased
biliary excretion in patients with Dubin-Johnson syndrome (MRP2-deficiency)
administered 99mTc-MEB analogs(5). 99mTc-MEB basolateral efflux was increased in TR−
rat SCH compared to WT, and in the presence of MK571 (Fig. 3A), while intracellular
accumulation of 99mTc-MEB was unchanged (Table 1). These important findings suggest
that this probe can be redirected from biliary excretion to efflux across the basolateral
membrane. This increase in basolateral efflux also could be due, in part, to inhibition
of 99mTc-MEB hepatic re-uptake, because MK571 has been shown to inhibit OATP1B3
with a reported Ki of 0.6μM(47).
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Further studies were conducted to investigate the efflux processes involved in 99mTc-MIBI
hepatic disposition. The absence of Mrp2 in TR− rat SCH did not alter basolateral or
canalicular efflux, suggesting that either Mrp2 is not involved, or other proteins (e.g. P-gp)
are able to fully compensate (Fig. 3B). In TR− rats, 99mTc-MIBI hepatic scintigraphy and
biliary excretion were unchanged compared to WT control rats(14). 99mTc-MIBI efflux was
assessed in the presence of 20μM GF120918, a concentration 10-fold greater than
previously used to inhibit P-gp in rat SCH(48). This concentration was selected based on
studies in cancer cell lines expressing multidrug resistance transport proteins (P-gp and
Bcrp) demonstrating GF120918 is a more potent inhibitor of P-gp than Bcrp by an order of
magnitude or more (49), and the use of 10 μM GF120918 in isolated perfused rat livers to
impair Bcrp-mediated biliary excretion of 4-methylumbelliferyl sulfate generated in the
hepatocyte(50). As expected, 99mTc-MIBI canalicular efflux was GF120918-sensitive,
consistent with a role for P-gp and/or Bcrp in 99mTc-MIBI biliary excretion.
Surprisingly, 99mTc-MIBI basolateral efflux was GF120918-sensitive, suggesting
involvement of an active transport process. Hepatocellular accumulation of 99mTc-MIBI
increased in the presence of GF120918 (Table 1) due to decreased basolateral and
canalicular efflux of 99mTc-MIBI (Fig. 3B).
In order to further investigate the transport processes involved in 99mTc-MIBI biliary
excretion, accumulation studies were conducted in rat SCH. The involvement of Bcrp in the
biliary excretion of 99mTc-MIBI was assessed with the use of RNAi knockdown of Bcrp, as
confirmed by immunoblot (Fig. 4B), and significantly impaired biliary excretion of the rat
Bcrp probe substrate nitrofurantoin (Fig. 4C). This approach using adenoviral vectors
expressing a non-target control (siNT) and short hairpin RNA targeting Bcrp (siBcrp) has
been shown to efficiently and specifically knock down Bcrp in rat SCH(23). Bcrp
knockdown did not affect 99mTc-MIBI cellular accumulation, biliary excretion or in vitro
Clbiliary (Fig. 4A). 99mTc-MIBI biliary excretion was inhibited completely by 2μM
GF120918 (Fig. 4A), used previously to inhibit P-gp in rat SCH(48). Cellular accumulation
also increased in the presence of GF120918 (Fig. 4A), suggesting that P-gp is the primary
protein responsible for the biliary excretion of 99mTc-MIBI. These findings are in agreement
with published in vitro data demonstrating the affinity of 99mTc-MIBI for P-gp in
overexpressing cancer cell lines(51, 52) and with human in vivo data; 99mTc-MIBI biliary
elimination was reduced and/or hepatic 99mTc-MIBI retention was increased based on
scintigraphy in humans with single nucleotide polymorphisms in the ABCB1 gene resulting
in decreased P-gp function(10), and in cancer patients administered 99mTc-MIBI and the P-
gp inhibitor PSC833(9, 11).
Species differences existed in the fraction of canalicular vs. basolateral efflux of 99mTc-
MEB in rat (38.0% vs. 62.0% of total efflux, respectively) compared to human (73.3% vs.
26.7% of total efflux, respectively; Fig. 3A) SCH. These in vitro findings support the
clinical observation that biliary clearance is rapid and extensive in humans; ~84% of a
2.3mCi dose of intravenously administered 99mTc-MEB was recovered in bile in healthy
human subjects within 180 min(53). In rats, the biliary excretion profile of 99mTc-MEB may
be more prolonged due to basolateral efflux and subsequent reuptake by hepatocytes; ~95%
of a 0.25 mCi dose was recovered in the liver 30 min after intravenous administration(54).
In contrast, based on the fraction of canalicular vs. basolateral efflux of 99mTc-MIBI in rat
(36.8% vs. 63.2% of total efflux, respectively) and human (28.3% vs. 71.7% of total efflux,
respectively; Fig. 3B) SCH, basolateral excretion of 99mTc-MIBI appears to be the
preferential route of hepatic elimination of this probe in both rats and humans. This finding
is consistent with biliary recovery of only ~22% of a 3.1mCi dose of intravenously
administered 99mTc-MIBI in healthy human subjects(55). Overall, the efflux method in SCH
is useful for examining the preferential route of hepatic excretion (canalicular vs.
basolateral) and elucidating species differences in hepatic efflux.
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In summary, the hepatic uptake of 99mTc-MIBI appears to occur by passive
diffusion; 99mTc-MIBI biliary excretion is mediated by P-gp. 99mTc-MEB hepatic uptake is
predominantly Oatp-mediated with biliary excretion by Mrp2. Species differences exist
between rat and human in the total efflux and route of efflux for 99mTc-MEB. Preloading
SCH and measurement of efflux over 20min in SCH is a useful approach to investigate the
route of hepatic excretion (basolateral vs. canalicular), species differences in basolateral and
canalicular efflux, and compensatory changes in canalicular and basolateral efflux due to
impaired transport function associated with drug interactions, disease state alterations or
genetic variation.
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P-gp multidrug resistance protein P-glycoprotein
Bcrp breast cancer resistance protein
Mrp multidrug resistance-associated protein
siBcrp RNAi short hairpin knockdown of rat Bcrp
BEI biliary excretion index
Clbiliary in vitro biliary clearance




FBS fetal bovine serum
HBSS Hanks’ balanced salt solution
GF120918 N-(4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]-
phenyl)-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide
OCT organic cation transporter
OAT organic anion transporter
siNT non-target siRNA
NTCP sodium taurocholate cotransporter
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Initial uptake rate of (A) 99mTc-MEB (5μCi/mL), (B) 99mTc-MIBI (5μCi/mL), (C) 3H-
E217G (1μM), and (D) 14C-TEA (20μM) in suspended WT rat hepatocytes in the absence
and presence of transport protein inhibitors (mean percentage ± SEM; n=3 livers per group,
in duplicate or triplicate); *, p<0.05 versus control.
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Initial uptake rate of (A) 99mTc-MEB (5μCi/mL), (B) 3H-E217G (1μM), and (C) 14C-TEA
(20μM) in suspended human hepatocytes in the absence and presence of transport protein
inhibitors (mean percentage ± SEM; n=3 livers per group, in duplicate or triplicate); *,
p<0.05 versus control.
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99mTc-MEB (A) and 99mTc-MIBI (B) basolateral (dark grey bars) and canalicular (white
bars) efflux over 20 min (5μCi/mL, 20min preload) in day 4 rat (WT and TR−) and day 7
human (hatched) sandwich-cultured hepatocytes. Data were obtained after a 20-min efflux
phase in incubation medium containing standard (basolateral) or Ca+-free (basolateral +
canalicular) HBSS (mean ± SEM or Range; n=4 WT rat livers, n=3 TR− rat livers and n=2
human livers in triplicate; statistical analysis was performed on rat sandwich-cultured
hepatocyte data only), *, p<0.05 versus control.
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99mTc-MIBI (A) accumulation in cells+bile (black bars) and cells (white bars), biliary
excretion index (BEI) and in vitro Clbiliary determined after a 10-min incubation with 0.5
μCi/mL 99mTc-MIBI in day 4 WT sandwich-cultured rat hepatocytes non-infected or
infected with adenoviral vectors expressing short hairpin RNA targeting rat Bcrp (siBcrp) or
a non-target control (siNT) (representative data; mean ± SD; n=3 livers). Bcrp (B)
expression in day 4 non-infected (None) or sandwich-cultured rat hepatocytes infected with
adenoviral vectors siNT and siBcrp. Representative results are shown with β-actin as the
loading control. Nitrofurantoin (C) accumulation in cells+bile (black bars) and cells (white
bars), BEI and in vitro Clbiliary were determined after a 10-min incubation with 5 μM
nitrofurantoin in day 4 WT sandwich-cultured rat hepatocytes non-infected or infected with
siBcrp or siNT (representative data; mean ± SD).
Swift et al. Page 20


































































































































































































































































































































Pharm Res. Author manuscript; available in PMC 2011 September 1.
